Aravive logo
Aravive ARAV

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Aravive Income Statement 2011-2026 | ARAV

Annual Income Statement Aravive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

60.4 M 44.2 M 84.3 M 118 M 27.2 M 72.2 M 400 M 323 M 335 M 366 K 297 K 1.82 M

Shares

36.4 M 20.1 M 16.1 M 11.6 M 7.17 M 5.87 M 5.13 M 4.83 M 3.15 M 141 K 141 K 3.88 M

Historical Prices

1.66 2.2 6.81 8.54 5.83 9.6 131 39.4 119 - - -

Net Income

-76.3 M -39.2 M -30.5 M -18.2 M -76.3 M -85 M -95.8 M -82.2 M -57.5 M -18.5 M -13.2 M -7.17 M

Revenue

9.14 M 7.44 M 5.68 M 4.75 M 1.37 M 40 M - - - - - -

Gross Profit

- - 5.68 K - - - - - - - - -

Operating Income

-70.8 M -40.6 M -30.8 M -21.8 M -75.4 M -84.5 M -96.3 M -82.5 M -46.1 M -19.3 M -12.9 M -

Interest Expense

2.84 M 1.46 M -14 K 2.53 M 2.43 M 528 K 236 K 113 K -11.5 M 128 K 393 K -

EBITDA

-70 M -39.7 M -23.2 M -21.3 M -36 M -84.2 M -96.1 M -82.3 M -46 M -19.3 M -12.9 M -8.14 M

Operating Expenses

80 M 48.1 M 30.7 M 26.5 M 38.5 M 124 M 96.3 M 82.5 M 46.1 M 19.3 M 12.9 M 8.16 M

General and Administrative Expenses

13 M 10.6 M 13.1 M 13.7 M 27.4 M 29.9 M 24.3 M 22.5 M 13.5 M 4.43 M 1.94 M 1.78 M

All numbers in USD currency

Quarterly Income Statement Aravive

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

75.7 M 75.7 M 75.7 M 59.8 M 30.5 M 30.5 M 21.1 M 21 M 20.8 M 20.4 M 18.1 M 16.5 M 16.1 M 15.9 M 15 M 15 M 11.3 M 11.3 M 11.3 M 11.3 M 6.04 M 6.02 M 6 M 35.9 M 35.7 M 35.3 M 35 M 34.6 M 29.6 M 29.5 M 29.4 M 29.4 M 29.4 M 29.3 M 27.8 M 24.2 M 24.2 M 24.2 M 2.79 M 1.26 M 251 K 148 K 133 K - - - - - - - -

Net Income

21.2 M 18 M -50 M - -15.7 M -18.5 M -13.1 M - -11.1 M -7.1 M -8 M - -10.7 M -5.04 M -10.8 M - -6.14 M -3.04 M -4.7 M - -6.55 M -9.85 M -8.98 M 31.1 M -49.8 M -36.6 M -29.7 M -22.1 M -27.3 M -22.1 M -24.2 M -20.1 M -20.4 M -19.7 M -22 M -15.7 M -13.8 M -8.6 M -19.4 M -5.81 M -5.01 M -3.66 M -4.02 M - - - - - - - -

Revenue

2.76 M 1.27 M 1.49 M - 4.96 M 1.62 M 1.09 M - 2.41 M 3.79 M 256 K - - - - - 4.75 M 3.05 M 1.7 M - - - - 40 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.91 M -12.6 M -17.9 M - -16.5 M -19.4 M -15 M - -11.6 M -7.41 M -8.01 M - -10.7 M -5.72 M -10.3 M - -7 M -3.87 M -5.74 M - -6.22 M -9.44 M -8.52 M 31.1 M -49.7 M -36.2 M -29.7 M -22.5 M -27.4 M -22.3 M -24.1 M -20.2 M -20.5 M -19.5 M -22.3 M -15.9 M -14.1 M -8.5 M -7.58 M -5.86 M -5.26 M -3.98 M -4.18 M - - - - - - - -

Interest Expense

700 K 650 K 697 K - 738 K 705 K 703 K - 479 K 295 K -5 K - 31 K 656 K -701 K - 624 K 597 K 689 K - -593 K -656 K -657 K -547 K -262 K -521 K -261 K 446 K -39 K 59 K -230 K 32 K 91 K -236 K 226 K 244 K 208 K -141 K -11.8 M 44 K 128 K 128 K 128 K - - - - - - - -

EBITDA

- - -17.7 M - -15.9 M -19 M -14.8 M - -10.8 M -6.92 M -7.77 M - -9.1 M -4.57 M -10.2 M - -6.62 M -3.63 M -5.61 M - -5.24 M -9.2 M -8.4 M 31.1 M -49.6 M -36.1 M -29.6 M -22.5 M -27.3 M -22.2 M -24.1 M -20.2 M -20.4 M -19.4 M -22.2 M -15.9 M -14 M -8.48 M -7.58 M -5.86 M -5.25 M -3.97 M -4.18 M - - - - - - - -

Operating Expenses

11.7 M 13.9 M 19.4 M - 21.5 M 21 M 16.1 M - 14 M 11.2 M 8.26 M - 10.7 M 5.72 M 10.3 M - 7 M 6.93 M 7.44 M - 6.22 M 9.44 M 8.52 M 8.89 M 49.7 M 36.2 M 29.7 M 22.5 M 27.4 M 22.3 M 24.1 M 20.2 M 20.5 M 19.5 M 22.3 M 15.9 M 14.1 M 8.5 M 7.58 M 5.86 M 5.26 M 3.98 M 4.18 M - - - - - - - -

General and Administrative Expenses

2.94 M 3.07 M 3.49 M - 2.84 M 3.73 M 3.09 M - 2.64 M 3.08 M 2.38 M - 2.72 M 3.2 M 3.95 M - 3.16 M 3.29 M 4.59 M - 5.19 M 6 M 4.92 M 7.57 M 7.07 M 7.57 M 7.66 M 5.76 M 6.75 M 5.91 M 5.92 M 4.62 M 5.12 M 7.56 M 5.18 M 4.34 M 3.58 M 2.88 M 2.71 M 2.4 M 685 K 656 K 682 K - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Aravive (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.15 -2.68 % $ 2.54 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -3.48 % $ 4.47 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.7 -1.61 % $ 8.14 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.72 -2.75 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.52 -2.46 % $ 1.39 B britainBritain
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 17.75 -0.79 % $ 852 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Certara Certara
CERT
$ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.91 -3.56 % $ 694 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 0.99 -3.28 % $ 72.7 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.0 0.5 % $ 2.93 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.19 -4.64 % $ 1.14 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 28.78 -1.44 % $ 1.67 B usaUSA
Champions Oncology Champions Oncology
CSBR
$ 6.0 -1.15 % $ 82 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.67 -3.42 % $ 116 M franceFrance
Alector Alector
ALEC
$ 2.11 -4.75 % $ 217 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 15.68 -2.4 % $ 779 M britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 4.17 0.24 % $ 296 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.27 2.44 % $ 5.92 B irlandaIrlanda